OLMA

SEC source: 0001905871-25-000004 · form4-12242025_021251.xml · derivative · entry 11

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,818

Underlying: Common Stock · 7,182 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: 25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001905871-25-000004 · form4-12242025_021251.xml · derivative · entry 10

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,182

Underlying: Common Stock · 42,818 shares

Expires 2034-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 6

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,997

F4 · price: The weighted average sale price for the transaction reported was $28.04, and the range of prices was between $27.655 and $28.36. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 5

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,997

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 4

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,815

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001831410-25-000007 · form4-12292025_091201.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 741,259

F1 · price: The weighted average sale price for the transaction reported was $28.53, and the range of prices was between $28.50 and $28.53. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001336504-25-000009 · form4-12242025_021230.xml · derivative · entry 11

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,080

Underlying: Common Stock · 12,070 shares

Expires 2035-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001336504-25-000009 · form4-12242025_021230.xml · derivative · entry 10

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,520 shares

Expires 2033-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

SEC source: 0001336504-25-000009 · form4-12242025_021230.xml · derivative · entry 9

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,520 shares

Expires 2032-06-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

SEC source: 0001336504-25-000009 · form4-12242025_021230.xml · derivative · entry 8

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 209,690 shares

Expires 2023-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

SEC source: 0001336504-25-000009 · form4-12242025_021230.xml · nonDerivative · entry 7

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · price: The weighted average sale price for the transaction reported was $30.48, and the range of prices was between $30.23 and $30.995. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001336504-25-000009 · form4-12242025_021230.xml · nonDerivative · entry 6

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,840

F2 · price: The weighted average sale price for the transaction reported was $29.71, and the range of prices was between $29.22 and $30.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001336504-25-000009 · form4-12242025_021230.xml · nonDerivative · entry 5

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 234,896

F1 · price: The weighted average sale price for the transaction reported was $28.83, and the range of prices was between $28.215 and $29.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001336504-25-000009 · form4-12242025_021230.xml · nonDerivative · entry 4

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 264,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001336504-25-000009 · form4-12242025_021230.xml · nonDerivative · entry 3

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 252,730

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001336504-25-000009 · form4-12242025_021230.xml · nonDerivative · entry 2

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 231,210

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001336504-25-000009 · form4-12242025_021230.xml · nonDerivative · entry 1

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,690

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001905871-25-000004 · form4-12242025_021251.xml · derivative · entry 9

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Common Stock · 40,000 shares

Expires 2034-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 3

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,997

F3 · price: The weighted average sale price for the transaction reported was $28.93, and the range of prices was between $28.51 and $29.44. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 2

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,918

F2 · price: The weighted average sale price for the transaction reported was $28.03, and the range of prices was between $27.50 and $28.49. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001905871-25-000004 · form4-12242025_021251.xml · nonDerivative · entry 1

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,997

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025.

SEC source: 0001831216-25-000004 · form4-12242025_021245.xml · nonDerivative · entry 4

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 542,881

SEC source: 0001831216-25-000004 · form4-12242025_021245.xml · nonDerivative · entry 3

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 551,881

F5 · price: The weighted average sale price for the transaction reported was $31.39, and the range of prices was between $31.00 and $31.595. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001831216-25-000004 · form4-12242025_021245.xml · nonDerivative · entry 2

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 557,927

F4 · price: The weighted average sale price for the transaction reported was $30.40, and the range of prices was between $30.00 and $30.995. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided

SEC source: 0001831216-25-000004 · form4-12242025_021245.xml · nonDerivative · entry 1

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 601,656

F1 · price: The weighted average sale price for the transaction reported was $28.08, and the range of prices was between $28.075 and $28.130. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F2 · balance_after: On December 11, 2024, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be understated by 60 shares. That error has been corrected in this Form 4.

F3 · balance_after: Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025.

SEC source: 0001579397-25-000007 · form4-12092025_091203.xml · nonDerivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 243,549

F1 · kind: The reporting person transferred 75,000 shares to the Kovacs 2025 Family Trust as a bona fide gift for no consideration. The reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust.

SEC source: 0001579397-25-000005 · form4-12012025_091201.xml · nonDerivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 318,549

F1 · kind: The reporting person transferred 225,000 shares to the Kovacs 2025 Family Trust as a bona fide gift for no consideration. The reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust.

SEC source: 0001162157-25-000005 · form4-11252025_061101.xml · nonDerivative · entry 2

RAPPAPORT ANDREW · CIK 0001162157 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reporting person transferred 35,868 to the Rappaport Family Foundation, a charitable foundation of which the reporting person is an officer, as a bona fide gift for no consideration. The reporting person has voting and dispositive power over all securities owned by the foundation.

SEC source: 0001162157-25-000005 · form4-11252025_061101.xml · derivative · entry 4

RAPPAPORT ANDREW · CIK 0001162157 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,868 shares

Expires 2025-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to the option are fully vested.

SEC source: 0001162157-25-000005 · form4-11252025_061101.xml · nonDerivative · entry 1

RAPPAPORT ANDREW · CIK 0001162157 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,868

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001831410-25-000004 · form4-09182025_090901.xml · nonDerivative · entry 4

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 117,028

F5 · price: The weighted average sale price for the transaction reported was $8.32, and the range of prices was between $8.29 and $8.33. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F4 · ownership.nature: The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.

SEC source: 0001831410-25-000004 · form4-09182025_090901.xml · nonDerivative · entry 2

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 744,140

F2 · price: The weighted average sale price for the transaction reported was $8.33, and the range of prices was between $8.28 and $8.37. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001831410-25-000004 · form4-09182025_090901.xml · nonDerivative · entry 3

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 120,114

F3 · price: The weighted average sale price for the transaction reported was $8.08, and the range of prices was between $8.04 and $8.08. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F4 · ownership.nature: The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.

SEC source: 0001831410-25-000004 · form4-09182025_090901.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 754,140

F1 · price: The weighted average sale price for the transaction reported was $8.04, and the range of prices was between $8.02 and $8.09. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0000921895-25-001761 · form407422010_06132025.xml · derivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · Director · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · Director · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · Director · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · Director · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 24,150

Underlying: Common stock, $0.0001 par value · 24,150 shares

Expires 2035-06-11

F7 · security: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F9 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date.

F7 · ownership.direct: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F7 · ownership.nature: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

SEC source: 0001415889-25-017232 · form4-06132025_050610.xml · derivative · entry 1

RAPPAPORT ANDREW · CIK 0001162157 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,150

Underlying: Common Stock · 24,150 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-017238 · form4-06132025_050624.xml · derivative · entry 1

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,150

Underlying: Common Stock · 24,150 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-017233 · form4-06132025_050612.xml · derivative · entry 1

BUTITTA CYNTHIA M · CIK 0001222082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,150

Underlying: Common Stock · 24,150 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-017237 · form4-06132025_050621.xml · derivative · entry 1

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,150

Underlying: Common Stock · 24,150 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-017239 · form4-06132025_050626.xml · derivative · entry 1

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,150

Underlying: Common Stock · 24,150 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-017240 · form4-06132025_050629.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,150

Underlying: Common Stock · 24,150 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-017236 · form4-06132025_050619.xml · derivative · entry 1

Hrustanovic Gorjan · CIK 0001821194 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,150

Underlying: Common Stock · 24,150 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

F2 · ownership.direct: The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001415889-25-017235 · form4-06132025_050617.xml · derivative · entry 1

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,150

Underlying: Common Stock · 24,150 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-017234 · form4-06132025_050615.xml · derivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,150

Underlying: Common Stock · 24,150 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-006151 · form4-03032025_090344.xml · derivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,000

Underlying: Common Stock · 320,000 shares

Expires 2035-02-27

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-25-006154 · form4-03032025_090314.xml · derivative · entry 1

Mitchell Shawnte · CIK 0001749432 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Common Stock · 450,000 shares

Expires 2035-02-27

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-25-006160 · form4-03032025_090348.xml · derivative · entry 1

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,000

Underlying: Common Stock · 205,000 shares

Expires 2035-02-27

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-25-006158 · form4-03032025_090328.xml · derivative · entry 1

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,000

Underlying: Common Stock · 205,000 shares

Expires 2035-02-27

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-25-006147 · form4-03032025_090310.xml · derivative · entry 1

Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common Stock · 650,000 shares

Expires 2035-02-27

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0000950170-25-004870 · ownership.xml · derivative · entry 3

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences IV General Partner, LLC · CIK 0001996931 · 10% owner

Bain Capital Life Sciences Fund IV, L.P. · CIK 0001996979 · 10% owner

Bain Capital Life Sciences Opportunities IV GP, LLC · CIK 0002015657 · 10% owner

Bain Capital Life Sciences Opportunities IV, L.P. · CIK 0002015553 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,500,000

Underlying: Common Stock · 3,500,000 shares

Expires not disclosed

F4 · kind: On January 10, 2025, BCLS Opportunities IV entered into an exchange agreement with the Issuer pursuant to which BCLS Opportunities IV exchanged 3,500,000 shares of Common Stock for a pre-funded warrant to purchase 3,500,000 shares of common stock in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The exchange transaction did not result in any change in the Bain Capital Life Sciences Entities pecuniary interest in the subject equity securities.

F5 · shares: BCLS Opportunities IV is prohibited from exercising this pre-funded warrant if the Bain Capital Life Sciences Entities would, in the aggregate, beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding immediately after giving effect to such exercise.

F4 · price: On January 10, 2025, BCLS Opportunities IV entered into an exchange agreement with the Issuer pursuant to which BCLS Opportunities IV exchanged 3,500,000 shares of Common Stock for a pre-funded warrant to purchase 3,500,000 shares of common stock in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The exchange transaction did not result in any change in the Bain Capital Life Sciences Entities pecuniary interest in the subject equity securities.

F6 · derivative.expiration_date: The pre-funded warrant does not expire.

F5 · derivative.underlying_shares: BCLS Opportunities IV is prohibited from exercising this pre-funded warrant if the Bain Capital Life Sciences Entities would, in the aggregate, beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding immediately after giving effect to such exercise.

F5 · balance_after: BCLS Opportunities IV is prohibited from exercising this pre-funded warrant if the Bain Capital Life Sciences Entities would, in the aggregate, beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding immediately after giving effect to such exercise.

F1 · ownership.nature: Represents securities held directly by Bain Capital Life Sciences Opportunities IV, L.P. ("BCLS Opportunities IV").

F2 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC ("BCLS Opportunities IV GP" and, together with BCLSI, BCLS Fund IV GP, BCLS Fund IV, BCLS Opportunities IV GP and BCLS Opportunities IV, the "Bain Capital Life Sciences Entities"), which is the general partner of BCLS Opportunities IV. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Opportunities IV. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.